Peripheral Vascular Disease
Conditions
Keywords
Atherectomy, Drug-Coated Balloon
Brief summary
This study is designed to collect information during a procedure that is routine care for treating a blockage in a blood vessel in the upper part of the participant's leg. This study is for data collection reasons to help doctors gain better understanding of the treatment of disease in the blood vessels of the legs. You will be treated with two devices that are routine, or standard of care, for your doctor to treat blockages in the blood vessel of the leg. The treatment is for a blockage or narrowing caused by plaque build-up in the blood vessel. Data will be collected to assess what length of time the blood vessel will be prevented from re-narrowing through twenty-four (24) months after the procedure.
Detailed description
This prospective study will evaluate the safety and effectiveness of two FDA 510(k) cleared DA products (Medtronic HawkOne® and TurboHawkM)19-21 and FDA approved drug-coated balloon (Medtronic IN.PACT® Admiral®)22 used in combination to debulk moderate and severely calcified femoropopliteal artery atherosclerotic lesions as defined by the published Peripheral Arterial Calcium Scoring System (PACSS) followed by treatment with the Medtronic IN.PACT® Admiral® DCB for the prevention of restenosis as assessed at 12-month follow-up. The data will be independently adjudicated by an angiographic and DUS core labs. An independent IVUS core lab to determine change in maximal luminal plaque area, pre- and post-atherectomy and post-adjunctive DCB therapy will adjudicate the assessment of debulking effectiveness. The operator will be blinded to all IVUS images and procedural success will be based on usual and customary angiographic visual assessments. The post-atherectomy plaque debulking effectiveness (change in plaque area) and vascular calcium severity as assessed by IVUS will be correlated with the angiographic metrics of RVD, pre- and post-treatment MLD, calcium grade (using PACSS), lesion length, sub-intimal wire passage, CTO length, and angiographic patterns of restenosis in all patients who sustain a CD-TLR through 12-months. All atherectomy specimens will be collected and provided to an independent histology laboratory for analysis of calcium content and vessel wall elements. The amount of embolic debris captured in the Spider® Distal Protection Device will be visually assessed. The study will validate PACSS definitions of moderate and severe calcium and its location (intimal, medial or mixed) as they relate to intra-procedural and Major Adverse Events (MAEs) through 30-day clinical follow-up (e.g., grade D-F dissections requiring provisional stenting, vessel perforation requiring an additional intervention or surgery, vessel thrombosis requiring adjunctive technologies and/or lytic agents, unplanned amputation, intra-procedure distal embolization, and CD-TLR).
Interventions
DEVICEMedtronic HawkOne® or TurboHawk™
Use of FDA Cleared Directional Atherectomy (DA) Devices. Medtronic HawkOne® Directional Atherectomy System or TurboHawk™ Plaque Excision System. DA followed by DCB will be performed in all enrolled subjects.
DEVICEMedtronic IN.PACT® Admiral® DCB
FDA Approved Drug Coated Balloon (DCB) Technology. Medtronic IN.PACT® Admiral® DCB will be used after DA.
DEVICEMedtronic Spider™ Distal Protection Device (DPD)
It is recommended that the Medtronic Spider™ Distal protection device (DPD) be paired with DA when used in complex, calcified lesions (TurboHawk™ IFU).
DEVICEVolcano Visions® PV .014 IVUS catheter
Lesion IVUS assessment using the Volcano Visions® PV .014 IVUS catheter will be required in all cases.
DEVICENitinol Stent Placement
Only FDA approved nitinol stents can be used if provisional stenting is required.
Sponsors
Medtronic
VIVA Physicians
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
General Inclusion Criteria: 1. Willing and able to provide informed consent; 2. Age ≥ 18 years of age; 3. Clinical evaluation determines Rutherford Category 2-4; 4. Willing to comply with all study requirements; 5. All lab work is within acceptable limits to undergo a percutaneous interventional procedure. 6. Life expectancy, in the investigator's opinion, of at least 24 months. Angiographic Inclusion Criteria: 1. RVD ≥ 4mm and ≤ 7mm; 2. Evidence of a ≥70% de novo or restenotic lesion or occlusion in the target lesion defined as in the superficial femoral artery and/or popliteal artery, located in the arterial segment starting at least 1 cm beyond the Common Femoral Artery (CFA) bifurcation between the superficial and profunda femoris arteries (proximal anatomical landmark) to the distal P2 segment of the popliteal artery; 3. Total lesion/occlusion length: a. ≥ 8 cm and ≤ 18 cm 4. Total occlusion length a. ≥ 6 cm and ≤10 cm 5. Stenosis or occlusion begins 1cm below the profunda-SFA bifurcation; 6. Femoral or popliteal stenosis or occlusion that does not extend beyond the P2 popliteal segment; 7. Minimum 1 patent infrapopliteal vessel to the foot with ≤ 50% diameter stenosis; 8. Grade 3 or 4 intimal, medial and/or mixed calcification per the PACSS as judged by the operator at the time of the procedure; 9. Index lesion fits within guidelines below: 9.1 If two lesions are ≤ 3 cm apart, treatment would be allowed as a single lesion providing they contain a segment of moderate or severe calcification and the total lesion length is ≥ 8 cm and ≤18 cm. 9.2 If more than one lesion is within the target vessel, and they are separated by \> 3 cm of normal vessel, one lesion must be designated by the investigator as the target lesion as long as the lesion meets all angiographic eligibility criteria. Only one index lesion is permitted for analysis, but study will allow a second lesion to be treated as a non-target lesion. 10. Infrapopliteal lesion, if diagnosed, can be staged and treated \> 30 days after index procedure.
Exclusion criteria
General
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Primary Patency | One year | One-year primary patency (PSVR ≤2.4) and freedom from CD-TLR in subjects with long, moderate and severely calcified symptomatic femoropopliteal arterial stenoses and occlusions after treatment with DA+DCB. |
| Freedom from MAE | One month | Freedom from (MAEs) defined as freedom from flow-limiting dissections (D-F), vessel perforations, unplanned amputation, intra-procedure distal athero-embolization and clinically-driven TVR in subjects with long, moderate and severely calcified femoropopliteal lesions and occlusions through 30 day follow up. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| IVUS | Post Index Procedure | Core lab assessed correlation between IVUS metrics of luminal diameter, change in plaque area and luminal gain pre- and post-atherectomy, and angiographic core lab assessment of pre- and post-percent diameter stenosis (%DS) and the extent of vascular calcification will be determined |
| PACCS scoring and related procedural complications | 1 month | The association of moderate and severe calcification as defined by the Peripheral Arterial Calcium Scoring System (PACSS) and the change in %DS, procedure related complications (residual stenosis ≥50%, vessel recoil and/or high-grade dissections requiring use of adjunct technologies) visual quantification of embolic material in the distal protection device and MAEs through 30-days will be assessed |
| Directional Atherectomy | Post Index Procedure | Directional Atherectomy device specific metrics of total directional atherectomy time as a function of lesion length, lesion morphology, and total procedure time. |
| Major Adverse Events thru 24 months | 24 months | Major adverse events through 24-months defined as composite clinically-driven target lesion revascularization (CD-TVR) defined as any re-intervention within the target vessel due to symptoms associated with a drop from post-intervention ABI/TBI \>20% or \>0.15, major unplanned amputation of the treated limb, and all-cause mortality post 30 day follow up through 2 year follow up. |
| Post procedure TVR | 6, 12, 24 months | TVR within 6, 12, 24 months post index procedure |
| Device Success | Post Index Procedure | Device Success: ≤ 30% residual stenosis after completion of directional atherectomy procedure (stand-alone) as assessed by the angiographic core lab. |
| Time to CD-TLR thru 24 months post procedure | 24 months | Time to first clinically-driven target lesion revascularization (TLR) through 24 months post-index procedure |
| Major target limb amputation post procedure | 6, 12, 24 months | Major target limb amputation within 6, 12, 24 months post index procedure |
| Thrombosis- target lesion post procedure | 6, 12, 24 months | Thrombosis at the target lesion site within 6, 12, 24 months post index procedure |
| Primary sustained clinical improvement | 6, 12, 24 months | Primary sustained clinical improvement: An improvement shift in the Rutherford classification of at least one class in amputation- and TVR-free surviving subjects at 6, 12, 24 months post procedure |
| Secondary sustained clinical improvement | 6, 12, 24 months | Secondary sustained clinical improvement: An improvement shift in the Rutherford classification of at least one class including the need for clinically-driven TVR in amputation-free surviving subjects at 6, 12, 24 months post index procedure |
| CD-TLR post procedure | 6, 12, 24 months | TLR within 6, 12, 24 months post index procedure |
| Procedural Success | Post Index Procedure | Procedural Success: ≤30% residual stenosis after completion of the directional atherectomy procedure and DCB as assessed by the angiographic core lab. |
Countries
United States
Outcome results
None listed